Top

European Journal of Drug Metabolism and Pharmacokinetics

Published in:

01-12-2011 | Original Paper

The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats

Authors: Jin-Hua Wen, Yu-Qing Xiong

Published in: European Journal of Drug Metabolism and Pharmacokinetics | Issue 4/2011

Abstract

The aim of this study was to explore potential herb–drug interaction between danshensu or ursolic acid and rosuvastatin. Compared to the control group given rosuvastatin alone, the concurrent use of danshensu (46 mg/kg) or ursolic acid (80 mg/kg) prior to the oral administration of rosuvastatin (100 mg/kg) increased the systemic exposure of rosuvastatin more than twofold. The plasma clearance of rosuvastatin was reduced to more than 57% in the presence of danshensu or ursolic acid. Rosuvastatin is minimally metabolized in the CYP2C9 isoenzyme pathway and to an even lesser extent in the CYP2C19 isoenzyme pathway. Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP. Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs.

Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN (2004) Protective effects of danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci 75:3157–3171PubMedCrossRef

Cheng TO (2006) Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease. Int J Cardiol 113:437–438PubMedCrossRef

Cheng ZH, Lou YP, Dai HJ, Xue F (1987) Studies on effects of “danshensu” on experimental microcirculatory disturbances and plasma lactic acid concentrations. Shanghai Yike Daxue Xuebao 14:25–29

Chunshan G, Amanda O, Rathnam C, Bruno H (2010) Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4:1–8CrossRef

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58(8):527–531PubMedCrossRef

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2003a) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73(4):322–329PubMedCrossRef

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003b) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol l55:94–99CrossRef

Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003c) The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59(1):51–56PubMed

Dong ZT, Jiang WD (1982) Effect of danshensu on isolated swine coronary artery perfusion preparation. Yaoxue Xuebao 17:226–228

Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D, Zhou HH (2008) The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83(3):471–476PubMedCrossRef

Handrean S, Paul DU (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Pharmacotherapy 9(12):2145–2160

Hiromi F, Hiroki S, Masayuki T, Ohdo S, Ohtani H, Sawada Y (2006) Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34:577–582CrossRef

Izzo AA, Di CG, Borrelli F, Ernst E (2006) Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 7:93–110

James MM (2005) Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am Soc Health-Syst Pharm 62:1033–1047

Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014–2023PubMedCrossRef

Kumar TR, Shitut NR, Kumar PK, Vinu MC, Kumar VV, Mullangi R, Srinivas NR (2006) Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr 20:881–887PubMedCrossRef

Li CZ, Yang SC, Zhao FD, Yang YQ, Yang CX, Zhang DC (1983) Anticoagulant studies of danshen. Zhongxiyi Jiehe Zazhi 3:297–299

Liao QF, Yang W, Jia Y, Chen XH, Gao QT, Bi KS (2005) LC–MS determination and pharmacokinetic studies of ursolic acid in rate plasma after administration of the traditional Chinese medicinal preparation Lu-Ying extract. Pharm Soc Jpn 125(6):509–515

Liu XQ, Luo XT, Ouyang XA (2001) Research advance of Fufang Danshen dosage forms. Shizhen Guoyi Guoyao 12:474–475

Mc TF, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87(suppl 5A):28B–32B

Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M (2002) Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 30:1158–1163PubMedCrossRef

Nezask K, Higaki K, Takeuchi M, Nakano M, Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379–388CrossRef

Olsson AG, McTaggart F, Raza A (2002) Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20:303–328PubMedCrossRef

Pan HY, Zhao XP, Zhou Q (2008) Pharmacokinetics and bioavailability study of danshensu in rat. China J Chin Materia Medica 33(2):146–148

Parfente’eva EP (1979) Effect of ursolic acid and its derivatives on lipid metabolism in experimental atherosclerosis. Chem Abstr 19:91–92

Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733PubMedCrossRef

Qiang F, Lee BJ, Lee W, Han HK (2009) Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats. Eur J Pharm Sci 37:413–417PubMedCrossRef

Richard HHM, Richard BKM (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–277CrossRef

Richard HH, Rommel GT, Brenda FL, Hartmut G, Wooin L, Christopher JL, Yi W, Richared BK (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793–1806CrossRef

Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75(5):455–463PubMedCrossRef

Somova LO, Nadar A, Rammanan P, Shode FO (2003) Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 10:115–121PubMedCrossRef

Su XH, Liang DQ, Wang XM (1992) The effect of danshensu (DS-182) of the injury of oxygen free radicals in myocardial mitochondria from rat myocardium. Zhongguo Bingli Shengli Zazhi 8:122–124

Sun CM, Cai HJ, Song SY (1991) New pharmacology effect of Danshensu. Zhong Chao Yao 21(1):20

Tang LH, Wang XM, Liang DQ (1989) The protection of DS-182 during reperfusion of total ischemia heart. Zhongguo Bingli Shengli Zazhi 5:65–69

Vasilenko YK, Lisevitskaya LI, Frolova LM, Parfenteva EP, Sk&e IV, Vasilenko AY, Kozharskii VV, Voskanyan VL (1982) Hypolipemic properties of triterpenoids. Farmakol Toksikol 45:66–70PubMed

Wen J, Xiong Y (2010) OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35:99–104PubMedCrossRef

White CM (2002) A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42:963–970PubMed

Xiong B (2004) Research advance of ursolic acid pharmacology. Foreign Med Sci, Sect Pharm 31:133–135

Zhao FQ, Wang AL, Wang L (1994) The distribution studies of Danshensu in rabbit body. J Chin Pharm 29(5):2911

Zhao BL, Zhao Y, Jiang W, Hou JW, Xin WJ (1996) Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia–reperfusion injury. Biochem Mol Biol Int 8:1171–1182

Zhou L, Zuo Z, Chow MSS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345–1359PubMedCrossRef

Title: The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats
Authors: Jin-Hua Wen
Yu-Qing Xiong
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: European Journal of Drug Metabolism and Pharmacokinetics / Issue 4/2011
Print ISSN: 0378-7966
Electronic ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-011-0048-7

At a glance: The STEP trials

Springer Medicine

The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Is saliva suitable as a biological fluid in relative bioavailability studies? Analysis of its performance in a 4 × 2 replicate crossover design

Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes

Pharmacokinetics of miriplatin in experimental dog models of hepatic or renal impairment

Acceleration of in vitro dissolution studies of sustained release dosage form of theophylline and in vitro–in vivo evaluations in terms of correlations

A nonlinear two compartmental fractional derivative model

Mathematical and physical model of gravity-fed infusion outflow: application to soft-bag-packed solutions